BELLUS Health Inc. and its subsidiaries, formerly known as Neurochem Inc. (BELLUS Health) is a global health company focused on the development and commercialization of products to provide health solutions to address critical unmet needs. In September 2008, the Company launched its first product, VIVIMIND (also known as trmiprostate and homotaurine), in Canada and globally on the Internet. On July 17, 2008, the Company completed the acquisition of Innodia Inc. (Innodia), a private company engaged in developing compounds for the treatment of diabetes, obesity and related metabolic conditions and diseases. The product candidates of the Company include eprodisate (KIACTA), NC-503 and prodrug of tramiprostate.